๐Ÿ‡ฎ๐Ÿ‡ชIreland
16ยฐC Partly Cloudy ยท Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Priya Life Science Clinical trial register
TrackersDrugsComparisonsAPI
Trackers› Clinical trials› Nashik
Clinical trial register · India

Clinical Trials in Nashik

Every study on the ClinicalTrials.gov registry that lists a site in India and is open, about to open, active-but-closed, or enrolling by invitation. Filter it, cite it, and take it away as a file.

Download CSV
Source: ClinicalTrials.gov, U.S. National Library of Medicine. Complete coverage โ€” all 1123 matching records held by the registry are in this view. Synced 21 Sep 2026, 03:16 UTC
1123
Studies in scope
all four open statuses
610
Recruiting now
open to new participants
222
Lead sponsors
across recruiting studies
Top sites
New Delhi 332 Mumbai 259 Hyderabad 237 Bangalore 193 Pune 189
Narrow the registerReset
Recruitment status
Phase
Lead sponsor
AstraZeneca29 Eli Lilly and Company9 Novartis Pharmaceuticals8 Pfizer8 Janssen Research & Development, LLC5
Site location
New Delhi332 Mumbai259 Hyderabad237 Bangalore193 Pune189
All 274 locations
Target enrolment
to
99 of 1123 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
Indian sites
Start
Recruiting
EASi-PROTKTโ„ข - A Study to Test Vicadrostat (BI 690517) Taken Together With Empagliflozin in People With Type 2 Diabetes, High Blood Pressure, and Cardiovascular Disease
NCT07064473Diabetes Mellitus, Type 2, Hypertension, Cardiovascular Diseases
Boehringer Ingelheim
Phase 3
11,800
Ahmedabad, Bengaluru, Bikaner, Kanpur, Kolkata, Maharashtra, Nagpur, Nashik
2025-07-22
Not yet open
A Study to Assess the Effect Probiotic Supplement on Immune Health in Teachers Prone to Upper Respiratory Tract Infection
NCT07033754URTI - Viral Upper Respiratory Tract Infection
Vedic Lifesciences Pvt. Ltd.
Not applicable
100
Vadodara, Nashik, Pune, New Delhi, Varanasi
2025-06-25
Recruiting
A Study to Test Whether Vicadrostat (BI 690517) in Combination With Empagliflozin Helps People With Heart Failure and a Weak Pumping Function of the Left Side of the Heart
NCT06935370Heart Failure
Boehringer Ingelheim
Phase 3
4,200
Aurangabad, Bangalore, Bikaner, Chennai, Kochi, Kolkata, Nashik, New Delhi
2025-05-20
Recruiting
Phase III Study of Rilvegostomig in Combination With Bevacizumab With or Without Tremelimumab as First-line Treatment of Hepatocellular Carcinoma
NCT06921785Hepatocellular Carcinoma
AstraZeneca
Phase 3
1,220
Ahmedabad, Bangalore, Binnฤguri, Dehradun, Delhi, Hyderabad, Mumbai, Nashik
2025-05-06
Active, closed
A Clinical Study to Evaluate the Efficacy of Native CT-IIยฎ in Individuals With Knee Osteoarthritis
NCT06917287Knee Osteoarthritis (OA)
Vedic Lifesciences Pvt. Ltd.
Not applicable
114
Mumbai, Nashik, Panvel
2025-04-20
Recruiting
Study of Trastuzumab Deruxtecan With Bevacizumab Versus Bevacizumab Monotherapy for First-line Maintenance in HER2-Expressing Ovarian Cancer (DESTINY-Ovarian01)
NCT06819007Ovarian Cancer
Daiichi Sankyo
Phase 3
582
Ahmedabad, Kolkata, Mumbai, Nagpur, Nashik, Pune, Vadodara, Varanasi
2025-03-19
Recruiting
A Study to Learn About the Study Medicine Called Rimegepant in Women When Used for Intermittent Prevention of Menstrual Migraine
NCT06641466Menstrual Migraine
Pfizer
Phase 3
723
Guntur, Ahmedabad, Mangaluru, Mumbai, Nagpur, Nashik, Ajmer, Lucknow
2025-03-11
Recruiting
A Study to Investigate the Efficacy, Safety and Tolerability of Remibrutinib Versus Placebo in Adult Patients With Generalized Myasthenia Gravis
NCT06744920Generalized Myasthenia Gravis
Novartis Pharmaceuticals
Phase 3
180
Gurugram, Mangalore, Nashik, New Delhi, Ludhiana, Vellore, Hyderabad, Lucknow
2025-02-07
Active, closed
Study of PF-07220060 With Letrozole in Adults With HR-positive HER2-negative Breast Cancer Who Have Not Received Anticancer Treatment for Advanced/Metastatic Disease
NCT06760637Breast Cancer
Pfizer
Phase 3
1,035
Surat, Gurugram, Bangalore, Mumbai, Nashik, Pune, Thane, New Delhi
2025-01-06
Recruiting
A Study to Assess the Efficacy and Safety of Induction Therapy With Afimkibart (Also Known as RO7790121) in Participants With Moderately to Severely Active Ulcerative Colitis
NCT06588855Moderately to Severely Active Ulcerative Colitis
Hoffmann-La Roche
Phase 3
350
Surat, Nagpur (urban), Nashik, Jaipur, Gachibowli, Secunderabad
2024-12-11
Recruiting
A Global Phase III Study of Rilvegostomig or Pembrolizumab Plus Chemotherapy for First-Line Treatment of Locally Advanced or Metastatic Non-Squamous NSCLC
NCT06627647Non-squamous Non-small Cell Lung Cancer
AstraZeneca
Phase 3
1,160
Calicut, Delhi, Gurgaon, Kolkata, Madurai, Mumbai, Nashik, New Delhi
2024-11-27
Recruiting
A Global Phase III Study of Rilvegostomig or Pembrolizumab Plus Chemotherapy for First-Line Treatment of Locally Advanced or Metastatic Squamous Non-small Cell Lung Cancer (NSCLC)
NCT06692738Non-small Cell Lung Cancer
AstraZeneca
Phase 3
1,160
Calicut, Delhi, Gurgaon, Kolkata, Madurai, Mumbai, Nashik, New Delhi
2024-11-18
Active, closed
A Study to Learn About the Study Medicine Called Rimegepant in Adolescents With Frequent Migraine
NCT06616194Migraine
Pfizer
Phase 3
200
Gurugram, Mangalore, Nashik, New Delhi
2024-11-15
Recruiting
Effect of a Multi-strain Probiotic on Recurrent Vulvovaginal Candidiasis
NCT06480604Vulvovaginal Candidiasis
The Archer-Daniels-Midland Company
Not applicable
126
Vadodara, Nashik, Pune, Sopฤra, Vasai
2024-10-15
Recruiting
A Study of Brentuximab Vedotin With Doxorubicin, Vinblastine and Dacarbazine in Adults With Hodgkin Lymphoma in India
NCT06831370Hodgkin Lymphoma
Takeda
Phase 4
124
Vijayawada, Guwahati, Surat, Bangalore, Puducherry, Nashik, Navi Mumbai, Pune
2024-08-28
Recruiting
First in Human Multicenter Open Name Dose-increase, Consolidation Method to Study Safety Drug-level in Blood & Drug Metabolism Clinical Activity of Oral JBI-778 in Lung Cancer Patients With, Without Brain Metastasis IDH Mutated WHO Grade 3,4 Recurrent Glioma, Salivary Glands Tumor
NCT07755397NSCLC Patients With EGFR Activating Mutation, Adenoid Cystic Carcinoma Metastatic, Adenoid Cystic Carcinoma of the Head and Neck
Jubilant Therapeutics India Limited
Phase 1
30
Surat, Bangalore, Mumbai, Nashik, Thane, New Delhi
2024-08-26
Recruiting
A Study of Surovatamig (AZD0486) Plus Rituximab in Previously Untreated Follicular Lymphoma Patients
NCT06549595Untreated Follicular Lymphoma
AstraZeneca
Phase 3
1,018
Delhi, Gurugram, Kolkata, Nashik, Surat, Thiruvananthapuram
2024-08-07
Recruiting
Saruparib (AZD5305) Plus Camizestrant or Plus Endocrine Therapy, Compared With CDK4/6 Inhibitor Plus Endocrine Therapy or Plus Camizestrant in HR-Positive, HER2-Negative (IHC 0, 1+, 2+/ ISH Non-amplified), BRCA1, BRCA2, or PALB2m Advanced Breast Cancer
NCT06380751Advanced Breast Cancer
AstraZeneca
Phase 3
788
Delhi, Kolkata, Lucknow, Mumbai, Mysuru, Nagpur, Nashik, New Delhi
2024-08-01
Recruiting
Efficacy and Safety of Zanidatamab With Standard-of-care Therapy Against Standard-of-care Therapy for Advanced HER2-positive Biliary Tract Cancer
NCT06282575Biliary Tract Cancer
Jazz Pharmaceuticals
Phase 3
286
Belagavi, Mumbai, Nashik, Hyderabad, Varanasi, New Delhi
2024-07-19
Active, closed
A Phase 3 Study of Barzolvolimab in Participants With Chronic Spontaneous Urticaria (CSU)
NCT06455202Chronic Spontaneous Urticaria
Celldex Therapeutics
Phase 3
976
Surat, Vadodara, Nagpur, Nashik, Pune, Jaipur, Kanpur, Ahmedabad
2024-07-19
Recruiting
Efficacy and Safety of a New Formulation of Oral Cladribine Compared With Placebo in Participants With Generalized Myasthenia Gravis (MyClad)
NCT06463587Generalized Myasthenia Gravis
Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany
Phase 3
264
Hyderabad, Bangalore, Mangalore, Nashik, Pune
2024-06-25
Recruiting
Phase 3 Extension Study to Evaluate Long-term Safety of Ianalumab in Participants With Systemic Lupus Erythematosus (SIRIUS-SLE Extension).
NCT06133972Systemic Lupus Erythematosus
Novartis Pharmaceuticals
Phase 3
550
Ahmedabad, Kozhikode, Kolhฤpur, Nagpur, Nashik, Pune, New Delhi
2024-05-21
Recruiting
Multicenter Study of Lumateperone for the Treatment of Bipolar Depression in Pediatric Patients
NCT06372964Bipolar Depression
Intra-Cellular Therapies, Inc.
Phase 3
384
Ahmedabad, Aurangabad, Nashik, Varanasi
2024-05-14
Recruiting
Phase III, Open-label Study of First-line Osimertinib With or Without Datopotamab Deruxtecan for EGFRm Locally Advanced or Metastatic Non-small Cell Lung Cancer
NCT06350097Non-small Cell Lung Cancer
AstraZeneca
Phase 3
582
Bangalore, Delhi, Hyderabad, Kolkata, Mysuru, Nagpur, Nashik, New Delhi
2024-04-29
Recruiting
Phase III, Open-label, Study of First-line Dato-DXd in Combination With Rilvegostomig for Advanced Non-squamous NSCLC With High PD-L1 Expression (TC โ‰ฅ 50%) and Without Actionable Genomic Alterations
NCT06357533Non-Small Cell Lung Cancer
AstraZeneca
Phase 3
675
Chennai, Dwฤrka, Jaipur, Kolkata, Marg Jaipur, Nagpur, Nashik, New Delhi
2024-04-11
Rows per page Showing 26–50 of 99
Previous 1 2 3 4 Next
Cite this view

Priya Life Science (2026). Clinical trial register: studies with an Indian investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 21 September 2026. https://priyalifescience.com/clinical-trials-india/city/nashik

Query this register directly
GET /api/trials?country=in&status=recruiting&format=json Try it now →
Listing here is informational and not medical advice; eligibility is determined by each study team. See also the Ireland, UK, EU, USA and China registers.